Skip to content

Factors Affecting Therapeutic Efficacy of Vaginal Laser Therapy for Female Stress Urinary Incontinence, and the Effect of Vaginal Laser Therapy on Overactive Bladder Syndrome and Sexual Function

Far Eastern Memorial Hospital

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03693690
Enrollment
200
Registered
2018-10-03
Start date
2018-10-01
Completion date
2023-12-31
Last updated
2023-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laser Thermotherapy, Stress Urinary Incontinence

Brief summary

The main aim of this study is to elucidate factors affecting treatment efficacy of vaginal laser therapy.

Detailed description

Laser thermotherapy can increase the stiffness of vaginal wall. It has been reported that vaginal laser therapy can be used to treat stress urinary incontinence. However, factor affecting treatment efficacy of vaginal laser therapy remains unknown. Thus the main aim of this study is to elucidate factors affecting treatment efficacy of vaginal laser therapy. Besides, the durability of vaginal laser therapy will be assessed. The above knowledge should be helpful for clinical decision making.

Interventions

PROCEDUREVaginal laser thermotherapy

Laser thermotherapy can increase the stiffness of vaginal wall. It has been reported that vaginal laser therapy can be used to treat stress urinary incontinence.

Sponsors

Far Eastern Memorial Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* \>20 years old female * had stress urinary incontinence symptoms * Sexual behavior * No urinary tract infection * At their own expense for vaginal laser therapy

Exclusion criteria

* Abnormal vaginal bleeding * Vaginal fistula

Design outcomes

Primary

MeasureTime frame
Global response assessment2 years

Secondary

MeasureTime frameDescription
Duration of sustained efficacy2 yearsDuration of global response assessment ≥ 2 at each visit

Countries

Taiwan

Contacts

Primary ContactSheng-Mou Hsiao, MD
smhsiao2@gmail.com+89667000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026